All In Biotech

Drug Trial Radar · NCT05594017

Pharmacological Modulation of Brain Oscillations in Memory Processing

Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 1, 2019

Primary completion

Nov 30, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
Oct 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn about the effects of scopolamine (an anticholinergic drug) on areas of the brain involved in memory, and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed. The main questions it aims to answer are 1) whether scopolamine changes memory activity solely at encoding (the time when the person perceives and determines to remember an item or event) as has previously been found, or if it also can selectively impact retrieval (when the item or event which has been processed is recalled or remembered), and 2) what the nature of the brain activity changes is. Participants will complete two treatment arms. One of these will be with the drug, and the other will be with a saline solution, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal and/or spatial task each of the two days. An anesthesiologist will administer either the drug or the saline at a critical point which addresses both of the research questions. Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and at what time point during memory formation.

Conditions

  • Epilepsy
  • Seizures
  • Cognitive Impairment, Mild
  • Memory Disorders
  • Memory Loss

Interventions

  • Scopolamine (0.4mg)Drug

    Patient receives a dose of scopolamine (0.4mg) via IV fifteen minutes prior to spatial or episodic memory task/completion.

  • PlaceboDrug

    Patient receives a dose of saline via IV fifteen minutes prior to spatial or episodic memory task/completion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
  2. Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
  3. Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
  4. Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
  5. Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
  6. Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
  7. Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
  8. Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.